Paltusotine

DRUG6 trials

Conditions

AcromegalyCarcinoidCarcinoid Intestine TumorCarcinoid SyndromeCarcinoid Syndrome DiarrheaCarcinoid TumorCarcinoid Tumor of CecumCarcinoid Tumor of Ileum

Phase 2

An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge)

CompletedNCT03789656

Crinetics Pharmaceuticals Inc.Acromegaly

Start: 2019-03-12End: 2020-08-31Updated: 2025-02-17

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)

CompletedNCT03792555

Crinetics Pharmaceuticals Inc.Acromegaly

Start: 2019-03-11End: 2020-08-12Updated: 2025-03-17

A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)

TerminatedNCT04261712

Crinetics Pharmaceuticals Inc.Acromegaly

Start: 2020-01-29End: 2026-06-30Updated: 2026-07-29

Phase 3

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly

TerminatedNCT04837040

Crinetics Pharmaceuticals Inc.Acromegaly

Start: 2021-05-12End: 2026-05-29Updated: 2026-07-15

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)

TerminatedNCT05192382

Crinetics Pharmaceuticals Inc.Acromegaly

Start: 2021-12-17End: 2026-06-02Updated: 2026-07-15

Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

RecruitingNCT07087054

Crinetics Pharmaceuticals Inc.Carcinoid, Carcinoid Intestine Tumor, Carcinoid Syndrome +6

Start: 2025-11-19End: 2030-01-01Target: 141Updated: 2026-09-15

Journal of Clinical Oncology2026-01-10

12535 Efficacy And Safety Of Once-daily Oral Paltusotine In Medically Untreated Patients With Acromegaly: Results From The Phase 3, Randomized, Placebo-controlled Pathfndr-2 Study

Journal of the Endocrine Society2024-10-018 citations

8404 Use of the Acromegaly Symptom Diary (ASD) in a Phase 3, Placebo-Controlled Study of Once-Daily, Oral Paltusotine in Patients With Acromegaly Switched From Injected Octreotide or Lanreotide

Journal of the Endocrine Society2024-10-01

OR01-01 Oral, Once-daily, Paltusotine (Non-peptide Selective Somatostatin Receptor Subtype 2 Agonist) Therapy In Patients With Acromegaly Is Associated With Long-term Biochemical And Symptom Control And Is Preferred Over Injectable Somatostatin-Receptor Ligands

Journal of the Endocrine Society2023-10-013 citations

Development and evaluation of the Acromegaly Symptom Diary

Journal of Patient-Reported Outcomes2023-02-1510 citations

Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers.

2022-01-0923 citations

Pharmacokinetics and Safety of an Improved Oral Formulation of Paltusotine, a Selective, Non-Peptide Somatostatin Receptor 2 (SST2) Agonist for the Treatment of Acromegaly

Journal of the Endocrine Society2021-05-0113 citations

Safety and Efficacy of Switching Injected Peptide Long-Acting Somatostatin Receptor Ligands to Once Daily Oral Paltusotine: ACROBAT Edge Phase 2 Study

Journal of the Endocrine Society2021-05-014 citations

Paltusotine

Sponsors

Conditions

Phase 2

Phase 3

Related Papers